article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 130
article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Decoding ‘junk DNA’ The Human Genome Project and subsequent studies discovered that most of our DNA (approximately 98%) does not actually code for proteins, with humans having approximately 20,000 tox 25,000 protein-coding genes.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genomic projects exploit scale as clinical applications play catch-up

Pharmaceutical Technology

Analysing almost eight thousand tumours across 33 different cancers, researchers say this marks the first time that a framework was created to understand the role of internal factors in driving such genomic alterations. Genomic research have greatly expanded our understanding of disease pathophysiology over the years.

article thumbnail

Can Singapore become a global hub for biotech?

Drug Discovery World

Singapore is also leading the way in genomics, having founded The Genome Institute of Singapore as far back as 2000. Dr Gokhale expands on the country’s leadership role: “Singapore is a great example of integration of genomic medicine in healthcare via population scale research.

article thumbnail

Hong Kong reports 'first case' of virus reinfection

The Pharma Data

They say genome sequencing shows the two strains of the virus are “clearly different”, making it the world’s first proven case of reinfection. “And it should not negate the global drive to develop Covid-19 vaccines. Getty Images. “It is to be expected that the virus will naturally mutate over time.”

article thumbnail

Open science, genomics, and the quiet revolution in our approach to pharma

Drug Discovery World

Evan Floden , CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. Increasingly, major collaborative life sciences projects, like the Human Genome Project or Human Cell Atlas, are driving advancements and organisations – both public and private – are taking note.

Genome 52
article thumbnail

The Biotech Effect

Pharmaceutical Technology

“However, around the time of the Human Genome Project, there was a ‘land grab’ for the new technologies as big pharmaceuticals tried to catch up paying high prices to access technology platforms in areas such as genomics and high throughput screening.”

Antibody 130